100 ml contains: Ciprofloxacin lactate: 200 mg.

Ciprofloxacin is a 4-quinolone chemotherapic agent with bactericidal activity. It acts by the inhibition of the bacterial DNA-gyrase, interfering replication DNA. It is effective in vitro against a wide spectrum of Gram+ and Gram- organisms. The effectiveness curves show a quick bactericidal effect and it has been often found that minimum bactericidal concentrations are in the same range that MIC. It has not been observed a cross-resistance with penicillin, cephalosporin, aminoglycoside and tetracyclin. The resistant organisms to these antibiotics are generally sensitive to Ciprofloxacin. The concomitant administration with other antibacterial agents produces an additive effect.
Ciprofloxacin is effective against the following bacterias:
Gram+ organisms: Staph. aureus (including meticillin susceptible and meticillin resistant), Staph. pyogenes and Str. pneumoniae. Str. faecalis, M. tuberculosis and C. trachomatis are moderately sensitives.
Gram- organisms: E. coli, Klebsiellae, including K. pneumoniae and K. oxytoca, Enterobacter, Citrobacter, Edwardsiella tarda, Salmonella, Shigella, P. mirabilis, P. vulgaris, Pr. rettgeri, Pr. stuaartii, M. morganii, Serratia (including S. marcescens), Y. enterocolitica, P. aeruginosa, Acinetobacter, H. influenzae, H. parainfluenzae, H. ducreyi, N. gonorrhoeae, N. meningitidis, B. catarrhalis. Campylobacter, Aeromonas, Vibrio (including V. cholerae), Brucella melitensis, P. multocida and Legionella.
S. marcenses, Str. faecalis, Str. faecium, Str. pneumoniae, M. hominis, Micobacterium and anaerobios, are sensitive germs to ciprofloxacin but their sensitivity must be checked before the treatment is instaured.
P. aeruginosa may develop resistance during treatment with Ciprofloxacin, so, controls will be carried out to detect this possibility.
U. urealyticum, C. difficile and N. asteroides are generally resistant.
There is not available information about efficacy of Ciprofloxacin against T. pallidum.

Full Product Information